Live Breaking News & Updates on China Reimbursement List

The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs fully or partially reimbursed by the national basic health insurance in China covering 96% of the population or more than 1.36 billion people. ....

Mumbai , Maharashtra , India , China , Sun-pharma , National-medical-products-administration , China-medical-system-holdings-limited , China-national-reimbursement-drug-list , National-reimbursement-drug-list , Tildrakizumab , Specialty-drug , China-reimbursement-list